Clinical application and prospect of circulating tumor DNA

Kumar-Sinha C, Chinnaiyan A M. Precision oncology in the age of integrative genomics[J]. Nat Biotechnol, 2018, 36(1): 46-60. doi: 10.1038/nbt.4017

Cohen J D, Javed A A, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J]. Proc Natl Acad Sci USA, 2017, 114(38): 10202-10207. doi: 10.1073/pnas.1704961114

Cohen J D, Li L, Wang Y X, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378): 926-930. doi: 10.1126/science.aar3247

Chan K C A, Woo J K S, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer[J]. N Engl J Med, 2017, 377(6): 513-522. doi: 10.1056/NEJMoa1701717

Wan J C M, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238. doi: 10.1038/nrc.2017.7

Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016, 6(5): 479-491. doi: 10.1158/2159-8290.CD-15-1483

Solé C, Tramonti D, Schramm M, et al. The circulating transcriptome as a source of biomarkers for melanoma[J]. Cancers (Basel), 2019, 11(1): E70-E79. doi: 10.3390/cancers11010070

Fu Q, Jiang H M, Wang Z B, et al. Injury factors alter miRNAs profiles of exosomes derived from islets and circulation[J]. Aging (Albany NY), 2018, 10(12): 3986-3999. http://www.ncbi.nlm.nih.gov/pubmed/30552311

Sorenson G D, Pribish D M, Valone F H, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood[J]. Cancer Epidemiol Biomarkers Prev, 1994, 3(1): 67-71. http://europepmc.org/abstract/MED/8118388

Mouliere F, Chandrananda D, Piskorz A M, et al. Enhanced detection of circulating tumor DNA by fragment size analysis[J]. Sci Transl Med, 2018, 10(466): 4921-4929. doi: 10.1126/scitranslmed.aat4921

De Mattos-Arruda L, Mayor R, Ng C K Y, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma[J]. Nat Commun, 2015, 6: 8839-8844. doi: 10.1038/ncomms9839

Murtaza M, Dawson S J, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun, 2015, 6: 8760-8768. doi: 10.1038/ncomms9760

Kuo Y B, Chen J S, Fan C W, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer[J]. Clin Chim Acta, 2014, 433: 284-289. doi: 10.1016/j.cca.2014.03.024

Jamal-Hanjani M, Wilson G A, Horswell S, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer[J]. Ann Oncol, 2016, 27(5): 862-867. doi: 10.1093/annonc/mdw037

Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer[J]. Sci Transl Med, 2014, 6(254): 254125-254134. doi: 10.1126/scitranslmed.3009448

Bettegowda C, Sausen M, Leary R J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 22424-22434. doi: 10.1126/scitranslmed.3007094

Scherer F, Kurtz D M, Newman A M, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA[J]. Sci Transl Med, 2016, 8(364): 364155-364163. doi: 10.1126/scitranslmed.aai8545

Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J]. Science, 2014, 345(6193): 216-220. doi: 10.1126/science.1253533

Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism[J]. Clin Chem, 2000, 46(8 Pt 1): 1078-1084. http://www.ncbi.nlm.nih.gov/pubmed/10926886

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, et al. Genomic alterations in liquid biopsies from patients with bladder cancer[J]. Eur Urol, 2016, 70(1): 75-82. doi: 10.1016/j.eururo.2016.01.007

Wang Y X, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord[J]. Proc Natl Acad Sci USA, 2015, 112(31): 9704-9709. doi: 10.1073/pnas.1511694112

Pan W Y, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid[J]. Clin Chem, 2015, 61(3): 514-522. doi: 10.1373/clinchem.2014.235457

Fernando M R, Chen K, Norton S, et al. A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage[J]. Prenat Diagn, 2010, 30(5): 418-424. doi: 10.1002/pd.2484

Norton S E, Lechner J M, Williams T, et al. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR[J]. Clin Biochem, 2013, 46(15): 1561-1565. doi: 10.1016/j.clinbiochem.2013.06.002

Norton S E, Luna K K, Lechner J M, et al. A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device[J]. J Clin Lab Anal, 2013, 27(4): 305-311. doi: 10.1002/jcla.21603

Newton C R, Graham A, Heptinstall L E, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)[J]. Nucleic Acids Res, 1989, 17(7): 2503-2516. doi: 10.1093/nar/17.7.2503

Ryan S E, Ryan F, O'Dwyer V, et al. A real-time ARMS PCR/high-resolution melt curve assay for the detection of the three primary mitochondrial mutations in Leber's hereditary optic neuropathy[J]. Mol Vis, 2016, 22: 1169-1175. http://pubmedcentralcanada.ca/pmcc/articles/PMC5063091/

Medrano R F, de Oliveira C A. Guidelines for the tetra-primer ARMS-PCR technique development[J]. Mol Biotechnol, 2014, 56(7): 599-608. http://europepmc.org/abstract/med/24519268

Thierry A R, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA[J]. Nat Med, 2014, 20(4): 430-435. http://www.ncbi.nlm.nih.gov/pubmed/24658074

Zonta E, Garlan F, Pécuchet N, et al. Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations[J]. PLoS One, 2016, 11(7): e0159094-e0159104. doi: 10.1371/journal.pone.0159094

Kidess E, Heirich K, Wiggin M, et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform[J]. Oncotarget, 2015, 6(4): 2549-2561.

Newman A M, Bratman S V, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5): 548-554. http://pubmedcentralcanada.ca/pmcc/articles/PMC4016134/

Gale D, Lawson A R J, Howarth K, et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA[J]. PLoS One, 2018, 13(3): e0194630-e0194638. doi: 10.1371/journal.pone.0194630

Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA[J]. Sci Transl Med, 2012, 4(136): 13668-13673. http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=scitransmed&resid=4/136/136ra68

Lanman R B, Mortimer S A, Zill O A, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA[J]. PLoS One, 2015, 10(10): e0140712-e0140719. http://pubmedcentralcanada.ca/pmcc/articles/PMC4608804/

Newman A M, Lovejoy A F, Klass D M, et al. Integrated digital error suppression for improved detection of circulating tumor DNA[J]. Nat Biotechnol, 2016, 34(5): 547-555. http://www.nature.com/nbt/journal/v34/n5/abs/nbt.3520.html

Mao L, Hruban R H, Boyle J O, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer[J]. Cancer Res, 1994, 54(7): 1634-1637.

Gormally E, Vineis P, Matullo G, et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study[J]. Cancer Res, 2006, 66(13): 6871-6876.

Guo S C, Diep D, Plongthongkum N, et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA[J]. Nat Genet, 2017, 49(4): 635-642. http://pubmedcentralcanada.ca/pmcc/articles/PMC5374016/

Gandara D R, Paul S M, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9): 1441-1448.

Abbosh C, Birkbak N J, Wilson G A, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution[J]. Nature, 2017, 545(7655): 446-451. http://europepmc.org/abstract/MED/28622291

Parkinson C A, Gale D, Piskorz A M, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: A retrospective study[J]. PLoS Med, 2016, 13(12): e1002198-e1002205.

Chaudhuri A A, Chabon J J, Lovejoy A F, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling[J]. Cancer Discov, 2017, 7(12): 1394-1403.

Li L, Zhang J, Jiang X Y, et al. Promising clinical application of ctDNA in evaluating immunotherapy efficacy[J]. Am J Cancer Res, 2018, 8(10): 1947-1956. http://www.ncbi.nlm.nih.gov/pubmed/30416847

Xu R H, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161.

Bettegowda C, Sausen M, Leary R J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 22424-22431. http://www.tandfonline.com/servlet/linkout?suffix=CIT0069&dbid=8&doi=10.1586%2F14737159.2015.1110021&key=24553385

Schmitt M W, Kennedy S R, Salk J J, et al. Detection of ultra-rare mutations by next-generation sequencing[J]. Proc Natl Acad Sci, 2012, 109(36): 14508-14513. http://europepmc.org/articles/PMC3437896

Cancer Genome Atlas Research Network, Weinstein J N, Collisson E A, et al. The cancer genome atlas pan-cancer analysis project[J]. Nat Genet, 2013, 45(10): 1113-1120.

Amorim M G, Valieris R, Drummond R D, et al. A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies[J]. Sci Rep, 2017, 7(1): 14395-14403.

Chan K C, Jiang P Y, Chan C W, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing[J]. Proc Natl Acad Sci USA, 2013, 110(47): 18761-18768. http://www.tandfonline.com/servlet/linkout?suffix=CIT0015&dbid=8&doi=10.1080%2F10715762.2018.1443448&key=24191000

Kim Y, Jeon J, Mejia S, et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer[J]. Nat Commun, 2016, 7: 11906-11911. http://europepmc.org/articles/PMC4931234/

Mayers J R, Wu C, Clish C B, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development[J]. Nat Med, 2014, 20(10): 1193-1198.

Yuan Y C, Shi Y, Li C Y, et al. DeepGene: an advanced cancer type classifier based on deep learning and somatic point mutations[J]. BMC Bioinformatics, 2016, 17(Suppl 17): 476-479. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259816/

Torga G, Pienta K J. Patient-paired sample congruence between 2 commercial liquid biopsy tests[J]. JAMA Oncol, 2018, 4(6): 868-870.